You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioibérica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.


Condrosan® is indicated for symptomatic osteoarthritis treatment.

Information updated January 2019.

Composition and dose

Condrosan® contains chondroitin sulfate as an active substance, in boxes with 60, 400-mg hard gelatin capsules.

The recommended dose is 2 capsules per day, preferably taken at one time, for at least 3 months.

Condrosan® is a prescription drug, financed by Social Security, registered in Spain by the Spanish Agency of Medicines and Medical Devices (AEMPS).

It is also approved in other countries under the brand name Cartexan®. Please contact us for more information.  

Efficacy and safety

Recent clinical studies in patients with osteoarthritis demonstrate that treatment with chondroitin sulfate decreases the symptoms of osteoarthritis, such as pain and functional deficits, significantly more than the placebo and comparable to celecoxib, after 6 months of treatment, improving the movement of the affected joints, as such it is considered as a core treatment for osteoarthritis1,2. Various clinical studies have also shown that treatment with chondroitin sulfate significantly reduces the loss of cartilage volume after 12 months of treatment compared to celecoxib1. All this helps to improve the quality of life for patients with osteoarthritis.

This drug also features a carry over effect, so that the treatment effect lasts for 2 or 3 months after it is withdrawn3.

Additionally, the safety of chondroitin sulfate has been proven according to the Cochrane review and epidemiological studies4-6.


1. Pelletier JP, et al. Arthritis Res Ther. 2016 Nov 3;18(1):256.

2. Bruyère O, et al. Semin Arthritis Rheum. 2014 Dec;44(3):253-63.

3. Uebelhart D, et al. Osteoarthritis Cartilage. 2004 Apr;12(4):269-76.

4. de Abajo FJ, et al. Pharmacoepidemiol Drug Saf. 2014 Nov;23(11):1128-38.

5. García-Poza P, et al. J Thromb Haemost. 2015 May;13(5): 708-18.

6. Singh JA, et al. Cochrane Database Syst Rev. 2015 Jan 28;1:CD005614.

To consult these studies on Condrosan®, apart from the additional bibliography and other relevant contents on osteoarthritis, you can visit



Condrosan® is financed by Social Security.